|Bid||6.56 x 800|
|Ask||6.98 x 800|
|Day's Range||6.43 - 6.79|
|52 Week Range||1.27 - 9.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...
The Radnor, Pennsylvania-based company said it had a loss of 15 cents per share. The company's shares closed at $4.50. A year ago, they were trading at $1.38. _____ This story was generated by Automated ...
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected ...
Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017....
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits. The stock moved mostly on sympathy for SAGE ...
Success for Sage Therapeutics' postpartum depression drug bodes well for a related candidate from Marinus Pharmaceuticals.
Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.
Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder.
The Radnor, Pennsylvania-based company said it had a loss of 21 cents per share. The company's shares closed at $1.87. A year ago, they were trading at $1.67. _____ This story was generated by Automated ...
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.